| Patents for A61P 35 - Antineoplastic agents (221,099) |
|---|
| 08/03/2006 | WO2006079244A1 Recombined adenovirus p53 preparation for treating tumor |
| 08/03/2006 | WO2006079216A1 Liposomal compositions for parenteral delivery of agents |
| 08/03/2006 | WO2006079155A1 Molecules and chimeric molecules thereof |
| 08/03/2006 | WO2006066183A3 Novel saframycin analogs as therapeutic agents |
| 08/03/2006 | WO2006065480A3 Tetrahydrocarbazoles as active agents for inhibiting vegf production by translational control |
| 08/03/2006 | WO2006065479A3 Substituted phenols as active agents inhibiting vegf production |
| 08/03/2006 | WO2006064375A9 Aminoaryl substituted five-membered ring heterocyclic compounds for the treatment of diseases |
| 08/03/2006 | WO2006061417A3 Macrocyclic quinazole derivatives and their use as mtki |
| 08/03/2006 | WO2006058868A3 Substituted pteridines for treating inflammatory diseases |
| 08/03/2006 | WO2006057932A3 2-METHYLENE-18,19-DINOR-1α-HYDROXY-HOMOPREGNACALCIFEROL AND ITS USES |
| 08/03/2006 | WO2006050734A3 Potent lna oligonucleotides for the inhibition of hif-1a expression |
| 08/03/2006 | WO2006050109A3 Novel kinase inhibitors |
| 08/03/2006 | WO2006048768A3 Kit of parts designed for implementing an antitumoral or antiviral treatment in a mammal |
| 08/03/2006 | WO2006044421A3 Cardiac safe, rapid medication delivery |
| 08/03/2006 | WO2006037960A3 T-cell receptors containing a non-native disulfide interchain bond linked to therapeutic agents |
| 08/03/2006 | WO2006019950A3 Conjugates of a gm-csf moiety and a polymer |
| 08/03/2006 | WO2006015371A3 Humanized anti-cmet antagonists |
| 08/03/2006 | WO2005118580A3 Tricyclic compounds as inhibitors of the hypoxic signaling pathway |
| 08/03/2006 | WO2005092302A3 Use of camptothecin derivates for the treatment of proliferative diseases in a fixed dosing regimen |
| 08/03/2006 | WO2005079849A3 Compounds for enhanced cancer therapy |
| 08/03/2006 | WO2005073250A3 Medical treatment using an rna1 targeting a human notch signalling pathway member |
| 08/03/2006 | WO2005049651A3 Cancer diagnosis and therapy |
| 08/03/2006 | WO2004001381A8 Novel raag10 cell surface target and a family of antibodies recognizing that target |
| 08/03/2006 | US20060173198 Synthesis of dimeric, trimeric, tetrameric, pentameric, and higher oligomeric epicatechin-derived procyanidins having 4beta,8-interflavan linkages and their use to inhibit cancer cell growth through cell cycle arrest |
| 08/03/2006 | US20060173182 Process of preparing imatinib and imatinib prepared thereby |
| 08/03/2006 | US20060173161 Protein-binding doxorubicin peptide derivatives |
| 08/03/2006 | US20060173160 Synthesis and characterization of novel systems for guidance and vectorization of molecules of therapeutic interest towards target cells |
| 08/03/2006 | US20060173056 Proline derivatives and use thereof as drugs |
| 08/03/2006 | US20060173055 Pyrrole compounds useful as kinase inhibitors |
| 08/03/2006 | US20060173047 Substituted 2-oxo-3-phenyl-5-carbonylaminomethyl-1, 3-oxazolines and their use as anticoagulant and antithrombotics |
| 08/03/2006 | US20060173034 Novel 4-anilinoquinoline-3-carboxamides |
| 08/03/2006 | US20060173032 Isolation and structure of cribrostatin 6 |
| 08/03/2006 | US20060173030 Antitumoral analogs of lamellarins |
| 08/03/2006 | US20060173017 Novel pyrazolopyrimidines as cyclin dependent kinase inhibitors |
| 08/03/2006 | US20060173016 7-carboxamido- or sulfonamido-substituted: 2-Phenyl-3-cyclopropyl-7-(4-pyridylcarboxamido)pyrazolo[1.5a]pyrimidine; treatment of cancer; additional anticancer drug or radiotherapy. |
| 08/03/2006 | US20060173010 Modulators of TNF-alpha signaling |
| 08/03/2006 | US20060173009 Agent inducing increase in bone mass |
| 08/03/2006 | US20060173007 Compounds, compositions, and methods |
| 08/03/2006 | US20060173003 4-Heteroarylamino-7-H(hetero)aryl-substituted, e.g., [6-(propane-2-sulfonyl)-pyridin-3-yl]-[7-(3-trifluoromethyl-pyridin-2-yl)-quinazolin-4-yl ]-amine hydrochloride; the compounds inhibit binding of vanilloid ligands to capsaicin receptors and are used to treat neuropathic pain |
| 08/03/2006 | US20060172971 e.g. 2-[(2-bromo-4-fluoro-phenyl)-hydrazono]-propionic acid ethyl ester; protein tyrosine kinase inhibitor, but does not inhibit ATP binding to the protein tyrosine kinase; and as anticarcinogenic agent, psoriasis, atherosclerosis, or immune system activity |
| 08/03/2006 | US20060172966 Immunostimulatory G, U-containing oligoribonucleotides |
| 08/03/2006 | US20060172960 cellular senescence and immortalization; administering a telemerase inhibitor; reduced loss of telomere length; antiproliferative agents |
| 08/03/2006 | US20060172946 Having serine protease inhibitory activity |
| 08/03/2006 | US20060172930 Apoptosis-inducing gene and utilization of the same |
| 08/03/2006 | US20060172926 Aplidine for multiple myeloma treatment |
| 08/03/2006 | US20060172391 BMP-11 compositions |
| 08/03/2006 | US20060172352 Nuclear matrix proteins |
| 08/03/2006 | US20060172347 Method of diagnosis, treatment and useful agents for conditions characterised by modulation in the level of activin ssc |
| 08/03/2006 | US20060172288 methods of identifying susceptibility of cells to reovirus infection by measuring constitutive ras-MAP signaling; provides for reovirus treatment of mammals to treat proliferative disorders including breast tumors, a subset of tumors in which mutation of ras gene is not believed to play significant role |
| 08/03/2006 | US20060171984 Device having hydration inhibitor |
| 08/03/2006 | US20060171954 Antigen specific activated T-lymphocytes, detection and use |
| 08/03/2006 | US20060171953 Tumour-specific animal proteins |
| 08/03/2006 | US20060171941 Humanized anti-TAG-72 CC49 monoclonal antibodies; retain binding affinity for TAG-72 and have reduced immunogenicity, as compared to a parental HuCC49V10 antibody; carcinoma; antitumor agent |
| 08/03/2006 | US20060171934 Methods and compositions using cellular asialodeterminants and glycoconjugates for targeting cells to tissues and organs |
| 08/03/2006 | DE10394175T5 Zusammensetzung mit einem botanischen Extrakt mit Anti-Krebs- oder phytoöstrogener Aktivität, enthaltend Prenyflavonoide Composition with a botanical extract with anti-cancer activity or phytoöstrogener containing Prenyflavonoide |
| 08/03/2006 | CA2596527A1 Igf-1r inhibitors |
| 08/03/2006 | CA2596232A1 The use of emip as cancer therapeutics in combination with electron beam irradiation or adjuvant treatment |
| 08/03/2006 | CA2596230A1 Composition for inhibiting expression of target gene |
| 08/03/2006 | CA2596131A1 Liposomal compositions for parenteral delivery of agents |
| 08/03/2006 | CA2596060A1 Novel pyrimidine nucleoside compound or salt thereof |
| 08/03/2006 | CA2595959A1 Methods for treating renal cell carcinoma |
| 08/03/2006 | CA2595874A1 The new use of recombinant adenovirus-p53 agent in treatment of tumor patients |
| 08/03/2006 | CA2595848A1 Erastin and erastin binding proteins, and uses thereof |
| 08/03/2006 | CA2595749A1 Combination therapy with triterpenoid compounds and proteasome inhibitors |
| 08/03/2006 | CA2595711A1 Methods and compositions using 4-amino-2-(3-methyl-2,6-dioxopiperidin-3-yl)-isoindole-1-3-dione |
| 08/03/2006 | CA2595676A1 Molecules and chimeric molecules thereof |
| 08/03/2006 | CA2595247A1 Indolopyridines, benzofuranopyridines and benzothienopyridines |
| 08/03/2006 | CA2594837A1 Novel indolopyridines, benzofuranopyridines and benzothienopyridines |
| 08/03/2006 | CA2594713A1 Anticancer drug containing .alpha.,.alpha.,.alpha.-trifluorothymidine and thymidine phosphorylase inhibitor |
| 08/03/2006 | CA2594708A1 Chemical compounds |
| 08/03/2006 | CA2594687A1 Use of pyrimidylaminobenzamides for the treatment of diseases that respond to modulation of tie-2 kinase activity |
| 08/03/2006 | CA2567789A1 Abasic oligonucleotide as carrier platform for antigen and immunostimulatory agonist and antagonist |
| 08/02/2006 | EP1686181A2 Methods for enhanced virus-mediated DNA transfer using molecules with virus-and cell-binding domains |
| 08/02/2006 | EP1686136A1 Novel glycoprotein and medicinal composition containing the same |
| 08/02/2006 | EP1686130A1 Pyrrolo[2,3-d]pyrimidine compounds as immunosuppressive agents |
| 08/02/2006 | EP1686124A1 Wortmannin analogs and methods of using same |
| 08/02/2006 | EP1686122A1 Antitumor agent |
| 08/02/2006 | EP1686120A2 Methods and compositions utilizing quinazolinones |
| 08/02/2006 | EP1685846A1 Antitumor agent |
| 08/02/2006 | EP1685842A2 Vascular endothelial growth factor (VEGF) nucleic acid ligand complexes |
| 08/02/2006 | EP1685835A2 Long term administration of sub-therapeutic dose levels of pharmacologically active agents |
| 08/02/2006 | EP1685832A1 Nerve regeneration promoters |
| 08/02/2006 | EP1685153A1 Targeting compositions and preparation thereof |
| 08/02/2006 | EP1685146A1 CRYSTALLINE COMPOUND OF 4'-DEMETHYL-4'-PHOSPHATE-2",3"-BISPENTAFLUOROPHENOXYACETYL-4",6"-ETHYLIDENE-ß-D-EPIPODOPHYLLOTOXIN GLUCOSIDE EITHER IN ITS FREE FORM OR SOLVATED WITH ETHANOL |
| 08/02/2006 | EP1685140A1 Isoflavonoid prodrugs, compositions thereof and therapeutic methods involving same |
| 08/02/2006 | EP1685136A1 Use of thienopyrimidines |
| 08/02/2006 | EP1685134A1 Novel chelidonine derivatives, methods for the production thereof, and use thereof for producing pharmaceutical agents |
| 08/02/2006 | EP1685127A1 Heterocyclyl-substituted oxetanes for the treatment of proliferative or infectious diseases |
| 08/02/2006 | EP1685116A1 Quinazoline derivatives |
| 08/02/2006 | EP1684810A1 Polybiotin compounds for magnetic resonance imagining and drug delivery |
| 08/02/2006 | EP1684809A1 Chelate based scaffolds in tumor targeting |
| 08/02/2006 | EP1684802A2 Immunogenic compositions |
| 08/02/2006 | EP1684795A1 Methods and agents for the treatment of cancer |
| 08/02/2006 | EP1684790A2 Homogeneous preparations of chimeric proteins |
| 08/02/2006 | EP1684780A1 The use of a polyphenol for the treatment of a cancerous or pre-cancerous lesion of the skin |
| 08/02/2006 | EP1684779A1 Method for controlling angiogenesis in animals |
| 08/02/2006 | EP1684770A1 Oligo-beta-(1,3)-glucan and monoclonal antibodies against cancer |
| 08/02/2006 | EP1684763A1 6-aryl-7-halo-imidazo[1,2-a]pyrimidines as anticancer agent |
| 08/02/2006 | EP1684758A2 Methods and compositions using thalidomide for the treatment and management of cancers and other diseases. |
| 08/02/2006 | EP1684747A1 Bisindolyl maleimides useful for treating prostate cancer and akt-mediated diseases |